Insulet Corporation (PODD) started 2026 with a bang, reporting first-quarter results that blew past analyst expectations. The insulin pump maker posted earnings of $1.42 per share, easily topping the $1.20 consensus estimate and jumping from $1.02 a year ago. Revenue came in at $761.7 million, also ahead of the $728.4 million analysts were looking for, according to market data.
The star of the show was the Omnipod platform, which generated $758.4 million in revenue — a 36.9% increase. International sales were particularly impressive, surging 59.4%, while U.S. Omnipod revenue grew 28.3% to $515.6 million. The company ended the quarter with $480.4 million in cash.
Looking ahead, Insulet raised its full-year 2026 revenue guidance to a range of $3.277 billion to $3.331 billion, up from the previous $3.250 billion to $3.304 billion. That's right around the $3.307 billion analyst estimate. For the second quarter, the company expects sales between $778.9 million and $791.9 million, in line with the $787.1 million consensus. Earnings for the full year are expected to exceed $6.21 per share, slightly below the $6.36 analyst estimate.
“We started the year strong, delivering continued growth momentum and robust operating margin expansion in the first quarter,” said Ashley McEvoy, President and CEO. She added that the company is scaling global operations and accelerating innovation to hit its long-term goals.
Investors liked what they heard. Insulet shares jumped 4.46% in premarket trading Wednesday to $175.00.
